Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study

Trial Profile

Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BioGeneriX; Teva Pharmaceutical Industries
  • Most Recent Events

    • 25 Jun 2014 New trial record
    • 18 Nov 2013 According to the Teva Pharmaceuticals media release, the safety of Filgrastim [Granix] was evaluated in this trial and another two phase III trial in patients receiving myelosuppressive chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top